- Oral presentation
- Open Access
Prelamin accumulation in primary endothelial cells induces premature senescence and activation
© Bonello-Palot and Badens 2015
- Published: 11 November 2015
- Progenitor Endothelial Cell
- Cell Senescence
- Premature Senescence
Defects in lamin A maturation result in premature aging syndromes and severe atherosclerosis as observed in Hutchinson-Gilford Progeria Syndrome. In age-related atherosclerosis, several features of cells senescence have been characterized in endothelial cells lamin A alterations. We propose a cellular model to study lamin A-related senescence in primary endothelial cells. In this model, lamin A defects were induced by protease inhibitor (PI: Atazanavir) treatment during 48h on normal cells issued from placenta (human umbilical vein (HUVEC) or cord blood (ECFC)). We showed that PI treatment led to the accumulation of farnesylated prelamin A and induced nuclear shape abnormalities and premature senescence in both HUVEC and ECFC. ICAM-1-dependent activation was present and monocytes adhesion was increased in HUVEC whereas ability to generate microvascular network in matrigel was decreased for ECFC. The effects of PI treatment on nuclei shape were reversed when cells were PI-treated in combination with Pravastatin and Zoledronate in both mature and progenitor endothelial cells. Reversion also was demonstrated with 2 antisens-oligonucleotides targeted toward lamin A specific splice sites. This study confirms that PI treatment reproduces premature senescence due to lamin A maturation defects in primary endothelial cells after a 2 days exposure. The cells used were extracted from full term and healthy neonates i.e. from individuals of age 0. This allows us to consider that other senescence pathways were not activated and that the observed alterations were specific of prelamin A accumulation. This model constitutes a valuable tool to test different approaches aimed at reversing specifically lamin A-related cells senescence.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.